Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Cypcar

Allergy & Immunology Asheville, NC Medical Doctor

NPI 1508857319 CMS profile 113905

14 McDowell St, Asheville, NC 28801

Open in the dashboard

General payments

$40,369

386 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,533,040 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Cypcar of Asheville, NC is reported in the CMS Open Payments database as having received $40,369 across 386 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,533,040 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,256 13
2024 General $316 6
2023 General $1,019 15
2022 General $9,142 97
2021 General $6,086 96
2020 General $5,861 58
2019 General $16,689 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Cypcar
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to David Cypcar were reported at $1,256. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year David Cypcar Allergy & Immunology median Middle half National median
2019 $16,689 $594 $163–$1,512 $163
2020 $5,861 $426 $106–$1,233 $114
2021 $6,086 $638 $157–$1,708 $132
2022 $9,142 $790 $205–$1,961 $149
2023 $1,019 $852 $220–$2,147 $160
2024 $316 $865 $203–$2,267 $164
2025 $1,256 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OptiNose US, Inc. $23,056 58 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $5,384 12 payments
  3. Novartis Pharmaceuticals Corporation $4,323 16 payments
  4. ALK-Abello, Inc $1,661 28 payments
  5. AstraZeneca Pharmaceuticals LP $1,231 41 payments
  6. GlaxoSmithKline, LLC. $1,212 51 payments
  7. CSL Behring $603 23 payments
  8. Genzyme Corporation $444 18 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $438 27 payments
  10. Pfizer Inc. $354 30 payments
  11. Other $1,663 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,455 13 payments
  2. Food and Beverage $8,671 344 payments
  3. Travel and Lodging $5,588 22 payments
  4. Consulting Fee $5,136 4 payments
  5. Honoraria $2,500 1 payment
  6. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. Xhance $23,056 58 payments
  2. Dust mite (D. farinae) $1,344 11 payments
  3. NUCALA $902 31 payments
  4. DUPIXENT $707 31 payments
  5. FASENRA Respiratory $354 5 payments
  6. Haegarda $312 13 payments
  7. SYMBICORT $312 13 payments
  8. FASENRA Respiratory $307 10 payments
  9. Odactra $301 16 payments
  10. Orladeyo $269 12 payments
  11. Other $3,860 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record